Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00075270 · ClinicalTrials.gov registry record · Phase 3
Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer
A Phase 3 study of Neoplasms, Breast, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 580
- Enrollment target
- 20
- Study locations
NCT00075270 is a Phase 3 study of Neoplasms, Breast that has completed, run by GlaxoSmithKline. The registered enrollment target is 580 participants, below the 1,003-participant average among 9 other Neoplasms, Breast trials with a reported enrollment target (42% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT00075270, a Phase 3 study of Neoplasms, Breast, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 580 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine the efficacy and safety of an oral dual tyrosine kinase inhibitor (GW572016) in combination with paclitaxel compared to paclitaxel alone in first line advanced or metastatic breast cancer.
Conditions Studied
Interventions
- DRUG Paclitaxel
- DRUG GW572016 (Lapatinib)
Study Locations (20)
California
- GSK Investigational Site - Fountain Valley
- GSK Investigational Site - La Jolla
- GSK Investigational Site - Rancho Mirage
- GSK Investigational Site - Vallejo
Florida
- GSK Investigational Site - Boca Raton
- GSK Investigational Site - Orlando
- GSK Investigational Site - Port Saint Lucie
- GSK Investigational Site - West Palm Beach
Georgia
- GSK Investigational Site - Atlanta
- GSK Investigational Site - Marietta
- GSK Investigational Site - Savannah
- GSK Investigational Site - Savannah
Arkansas
- GSK Investigational Site - Hot Springs
- GSK Investigational Site - Jonesboro
Arizona
- GSK Investigational Site - Tucson
Colorado
- GSK Investigational Site - Denver
Indiana
- GSK Investigational Site - Indianapolis
Kansas
- GSK Investigational Site - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 580 participants |
| Start Date | 2004-01 |
| Est. Completion | 2012-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00075270
The ClinicalTrials.gov registry entry for NCT00075270 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 580 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,003-participant average among 9 other Neoplasms, Breast trials with a reported enrollment target (42% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neoplasms, Breast appearing as the primary indexed condition, and to 2 interventions - of which Paclitaxel is the first listed.
NCT00075270 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT00075270 about?
NCT00075270 is a clinical study titled "Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer". The purpose of this study is to determine the efficacy and safety of an oral dual tyrosine kinase inhibitor (GW572016) in combination with paclitaxel compared to paclitaxel alone in first line advanced or metastatic breast cancer.
What is the current status of trial NCT00075270?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 580 participants. The study started on 2004-01. Estimated completion is 2012-03.
What conditions does trial NCT00075270 study?
This clinical trial studies the following conditions: Neoplasms, Breast.
What interventions are being tested in trial NCT00075270?
The interventions under investigation include: Paclitaxel (DRUG), GW572016 (Lapatinib) (DRUG).
Who is sponsoring clinical trial NCT00075270?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00075270 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms, Breast
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease
ACTIVE NOT RECRUITING · Phase 3
-
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D
COMPLETED · Phase 3
-
Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC
COMPLETED · Phase 2
-
Evaluating and Comparing Two Surgical Methods for Treatment of Early Stage Breast Cancer
COMPLETED · NA
-
Lapatinib In Chemotherapy-Naive Or Metastatic Breast Cancer
COMPLETED · Phase 2
-
Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.